SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,071+1.4%Dec 19 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bull-like who wrote (403)11/6/1998 7:01:00 PM
From: Anthony Wong  Read Replies (1) of 642
 
Excerpt from a Bloomberg article on PFE's analyst meeting (it would be at least 2000 before the drug is approved by the FDA):

Osteoporosis

For its osteoporosis drug, Pfizer said it intends to conduct
''head-to-head'' comparisons with competing products. Eli Lilly &
Co. makes a similar drug, Evista. Evista is the first of a class
of drugs that appear to mimic estrogen's benefits without causing
side effects. Lilly already is studying Evista for use in prevent
breast cancer and heart disease. The drug is approved for use in
osteoporosis, or a thinning of the bones that makes them more
fragile.

Pfizer said it has two likely compounds for its similar
drug. It expects to put the better of these two into so-called
Phase III trials next year. This is the last stage of testing
needed to apply for U.S. Food and Drug Administration approval.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News